Syntenin-1 Exosome Biogenesis Modulation Therapy for Neurodegeneration

10-Dimension Rubric Scoring

flowchart TD
    ideas_payload_syntenin_1_exoso["Syntenin-1 Exosome Biogenesis Modulation Therapy"]
    style ideas_payload_syntenin_1_exoso fill:#4fc3f7,stroke:#333,color:#000
    ideas_payload_synten_0["10-Dimension Rubric Scoring"]
    ideas_payload_syntenin_1_exoso -->|"includes"| ideas_payload_synten_0
    style ideas_payload_synten_0 fill:#81c784,stroke:#333,color:#000
    ideas_payload_synten_1["Disease Coverage Matrix"]
    ideas_payload_syntenin_1_exoso -->|"includes"| ideas_payload_synten_1
    style ideas_payload_synten_1 fill:#ef5350,stroke:#333,color:#000
    ideas_payload_synten_2["Category"]
    ideas_payload_syntenin_1_exoso -->|"includes"| ideas_payload_synten_2
    style ideas_payload_synten_2 fill:#ffd54f,stroke:#333,color:#000
    ideas_payload_synten_3["Therapeutic Target"]
    ideas_payload_syntenin_1_exoso -->|"includes"| ideas_payload_synten_3
    style ideas_payload_synten_3 fill:#ce93d8,stroke:#333,color:#000
    ideas_payload_synten_4["Primary Target: Syntenin-1 SDCBP"]
    ideas_payload_syntenin_1_exoso -->|"includes"| ideas_payload_synten_4
    style ideas_payload_synten_4 fill:#4fc3f7,stroke:#333,color:#000
    ideas_payload_synten_5["Secondary Targets"]
    ideas_payload_syntenin_1_exoso -->|"includes"| ideas_payload_synten_5
    style ideas_payload_synten_5 fill:#81c784,stroke:#333,color:#000

Total Score: 76/100

Disease Coverage Matrix

Category

Novel target (exosome biogenesis)

Therapeutic Target

Primary Target: Syntenin-1 (SDCBP)

Syntenin-1 (also known as SDCBP) is a small PDZ domain-containing scaffold protein that plays a critical role in exosome biogenesis by recruiting ALIX to intraluminal vesicles (ILVs) in multivesicular bodies (MVBs).

Secondary Targets

• ALIX (PD6A) — Essential cofactor for Syntenin-1-dependent exosome formation

• ESCRT-III subunits (CHMP4B/C, CHMP2A) — Downstream effectors of exosome release

• RAB27A/B — Regulators of MVB docking and exosome release (alternative pathway)

Key Mechanism

The Syntenin-ALIX Exosome Biogenesis Pathway

1. Syntenin-1 Recruitment: Syntenin-1 binds to phosphatidylinositol-4,5-bisphosphate (PIP2) on endosomal membranes via its N-terminal domain

2. ALIX Recruitment: Syntenin-1’s PDZ domains recruit ALIX (also known as PD6A) through direct protein-protein interaction

3. ESCRT-III Recruitment: ALIX recruits ESCRT-III subunits (CHMP4B/C, CHMP2A) to facilitate membrane scission

4. MVB-Exosome Release: The MVB fuses with the plasma membrane, releasing exosomes into the extracellular space

5. Pathogenic Cargo Loading: Disease-associated proteins (α-syn, tau, TDP-43, SOD1) are selectively packaged into exosomes during this process

Therapeutic Intervention Points

• Syntenin-1 small molecule inhibitors — Block PDZ domain interactions with ALIX

• ALIX inhibitors — Prevent Syntenin-ALIX complex formation

• Peptide blockers — Synthetic peptides mimicking Syntenin-1’s ALIX-binding motif

• RNAi/shRNA — Reduce Syntenin-1 expression via AAV-delivered constructs

Evidence for Therapeutic Relevance

• Roux et al., 2006 — Original identification of Syntenin-1 as ALIX interactor via BioID

• Baietti et al., 2012 — Demonstrated Syntenin-SPDP is required for exosome biogenesis in HeLa cells

• Larios et al., 2020 — Confirmed ALIX- and ESCRT-III-dependent sorting of transmembrane proteins into exosomes

• Gauthier et al., 2017 — Phosphorylated tau interacts with endosomal system and is secreted in exosomes

• Emmanouilidou et al., 2010 — Cell-produced α-syn is secreted in exosomes in a calcium-dependent manner

• Schneider & Simons, 2016 — Exosomes as vehicle for tau propagation between neurons

Rationale

Why This Target?

1. Upstream Mechanism: Unlike downstream aggregation inhibitors, this approach reduces the production of pathogenic exosomes at source

2. Genetic Validation: SDCBP (Syntenin-1) is widely expressed in neurons and glia; no known loss-of-function disease mutations suggest therapeutic inhibition is tolerable

3. Broad Disease Relevance: All major neurodegenerative proteinopathies involve exosomal propagation

4. Proof-of-Concept: Studies show reducing exosome release decreases pathological spreading in cell and animal models

Comparison to Existing Approaches

Combination Therapy Potential

Synergistic Combinations

1. Syntenin-1 Modulation + Autophagy Induction

   • Syntenin-1 inhibition reduces exosomal secretion

   • Autophagy enhancers increase intracellular clearance

   • Combined effect: Reduced pathological burden from both secretion and accumulation

2. Syntenin-1 Modulation + Aggregation Inhibitors

   • Exosome reduction + intracellular aggregation prevention

   • Two-pronged attack on proteostasis

3. Syntenin-1 Modulation + Microglia State Editing

   • Reduces exosomal burden on microglia

   • TREM2-LXR modulation improves microglial clearance

   • Synergistic restoration of proteostasis

De-risking Path

Preclinical Development

1. In vitro proof-of-concept (Year 1)

   • Screen small molecule inhibitors of Syntenin-1 PDZ domains

   • Test in neuron/iPSC cultures from AD/PD patients

   • Measure exosomal tau/α-syn secretion via ELISA/Western blot

2. Ex vivo validation (Year 1-2)

   • Patient-derived iPSC neurons

   • Measure reduction in exosomal pathogenic cargo

   • Confirm viability and normal cellular function

3. IND-enabling studies (Year 2)

   • GMP synthesis of lead compound

   • PK/PD studies in relevant species

   • GLP toxicology (rodent + non-rodent)

Clinical Development

4. Phase I (Year 3)

   • Single ascending dose in healthy volunteers

   • Safety, PK, target engagement biomarkers

5. Phase II (Year 3-4)

   • Biomarker-enriched patient population

   • Primary endpoint: Reduction in CSF exosomal p-tau/α-syn

   • Secondary: Clinical efficacy signals

Implementation Roadmap

Immediate Actions (0-6 months)

1. Establish Syntenin-1 assay for small molecule screening

2. Develop cell-based reporter for exosome release

3. Screen compound libraries (FDA-approved drugs, natural products)

4. Identify lead candidates

Near-term Goals (6-18 months)

1. Optimize lead compounds for BBB penetration

2. Establish in vivo PK/PD correlation

3. Conduct proof-of-concept studies in APP/PS1 or α-syn transgenic mice

4. Measure exosomal tau/α-syn in brain and CSF

Long-term Goals (18-36 months)

1. IND submission

2. Initiate clinical trials

3. Establish biomarker platform for patient selection

Risk Assessment